Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.

Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.

Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia

Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia

Regeneron Pharmaceuticals

Dupixent's recent clinical data suggest it is a viable treatment option for adult patients with chronic obstructive pulmonary disease (COPD). The medicine could top $3 billion in annual revenue for Sanofi and Regeneron to split.

Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?

Availability of the Q 1 202 3 Memorandum for modelling purposes

Press Release: Availability of the Q1 2023 Memorandum for modelling purposes

Provention Bio Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Provention Bio, Inc. (NasdaqGS: PRVB) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Provention will receive only $25.00 in cash for each share of Provention that they own.

PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB

Shares of Sanofi (NASDAQ: SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) finished with a gain of 9.68%, following promising news about the companies' jointly developed medication Dupixent.

Sanofi, Regeneron Shares Pop On Big News About COPD Treatment

The companies said Dupixent showed positive results in a late-stage study of current or former smokers with the killer disease.

Regeneron, Sanofi Look for Billions From COPD Drug

Dupixent was proven to be effective at treating a condition that causes chronic hives. The indication could generate $600 million in annual revenue for Sanofi and Regeneron to share.

Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?

Sanofi is reducing the price of its most important insulin product. A pending acquisition could help pick up the slack in diabetes care.

Is Sanofi Stock a Buy Now?

Amazon

Activision Blizzard

Comcast

Disney

Lululemon Athletica

Marriott

Netflix

NIKE

Vanguard Consumer Staples ETF

Warner Bros Discovery Inc

While you might already know that you can invest in consumer staples like food and tobacco products, you might not know that you can also invest in what people buy when they have more to spend. Consumer discretionary stocks come from companies that produce goods and services that consumers can choose to purchase but are not considered essential to their day-to-day lives.

11 Best Consumer Discretionary Stocks of 2023

VanEck Vectors Biotech ETF

iShares Nasdaq Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Simplify Health Care ETF

Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.

ETFs in Focus on Sanofi and Regeneron's COPD Drug Data

Sanofi (SNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sanofi (SNY) Moves 6.0% Higher: Will This Strength Last?

Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with "smoker's lung," leading SNY and REGN stocks to rocket. The post Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars appeared first on Investor's Business Daily.

Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars

Sanofi (SNY) and partner Regeneron's (REGN) Dupixent led to a 30% decline in exacerbations per a late-stage pivotal study on chronic obstructive pulmonary disease.

Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study

Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say "exceeded expectations."

Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD

French pharma multinational Sanofi's Dupixent drug has achieved impressive results in a late-stage trial to treat chronic obstructive pulmonary disease (COPD), aka ‘smoker's lung'. Developed jointly with US biotech group Regeneron, Dupixent caused a 30% reduction in moderate or severe acute exacerbations of COPD among a trial group of 939 current or former smokers.

Sanofi's blockbuster Dupixent drug clears major trial

Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with "smoker's lung," leading SNY and REGN stocks to rocket. The post Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung' appeared first on Investor's Business Daily.

Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'

Shares of Regeneron Pharmaceuticals Inc. REGN, -1.11% rallied about 7% in premarket trading on Thursday after the company said a pivotal Phase 3 clinical trial showed that Dupixent reduced exacerbations in people with uncontrolled chronic obstructive pulmonary disease (COPD), compared with placebo. U.S.-listed shares of Sanofi SNY, +0.47% , which co-developed Dupixent, were up about 6%.

Regeneron, Sanofi say Dupixent works in COPD

Dupixent ® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial

Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial

BAE Systems PLC

Legal & General Group PLC

Unilever

Similar to their American counterparts, the European Dividend Aristocrats offer investors dividend hikes and blue-chip stability.

European Dividend Aristocrats: The Best European Dividend Stocks

Sanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat severe atopic dermatitis in kids as young as six months old in Europe.

Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids

Dupixent ® (dupilumab) a pproved by European Commission as f irst and o nly t argeted m edicine for c hildren as y oung as s ix m onths o ld with s evere a topic d ermatitis

Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

Dupixent ® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of m oderate-to-severe a topic h and and f oot d ermatitis

Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Sanofi (SNY) plans to lower the prices of its most widely used insulin Lantus by upto 78% in the United States, effective January 2024.

Sanofi (SNY) to Reduce Lantus Insulin Price by Up to 78%

The French company will cap the monthly cost of insulin at $35, after Novo Nordisk and Eli Lilly also announced major price cuts earlier this month.

News for Sanofi Stock (SNY)